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Abstract
Aim. A total of 329 patients with hepatocellular carcinoma have been treated at our unit since 1990. Following the
randomized controlled trial in Hong Kong by Lau et al. in 1999, patients have been offered adjuvant lipiodol I-131. The aim
of this study was to determine the effectiveness of adjuvant lipiodol I-131, following potentially curative surgery with
resection and/or ablation, on overall and disease-free survival rates. Material and methods. The prospectively updated
hepatocellular carcinoma database was analysed retrospectively. A total of 34 patients were identified to have received
adjuvant lipiodol I-131 post-curative treatment with surgical resection and/or ablation. Patient demographics, clinical,
surgical, pathology, and survival data were collected and analysed. Results. Three patients received ablation alone, 24
resection, and 7 resection and ablation. Of the 34 patients treated, there were 2 possible cases of treatment-related fatality
(pneumonitis and liver failure). Potential prognostic factors studied for effect on survival included age, gender, serum AFP
concentration, Child-Pugh score, cirrhosis, tumor size, portal vein tumor thrombus, tumor rupture, and vascular and
margin involvement. The median follow-up duration was 23.3 months. The overall median survival was 40.1 months, while
the overall survival rates at 1, 2, 3, and 4 years were 87.1%, 71.7%, 60.7%, and 49.6%, respectively. Median duration to
recurrence was 22.3 months. Conclusion. Administration of adjuvant lipiodol I-131 is associated with good overall survival.
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Introduction
Hepatocellular carcinoma (HCC) is the fifth most
common malignancy with an annual worldwide in-
cidence of over half a million [1]. Despite the
improvements in surveillance, imaging technology,
surgical techniques, and perioperative care, the mor-
tality rate associated with the disease is still on the rise
[2,3]. In the United States, the mortality rate in-
creased from 1.7 per 100,000 in the period 1981 to
1985 to 2.4 per 100,000 in 1991 to 1995 [4]. The
most effective treatments available for HCC to date
are liver transplantation, surgical resection, and abla-
tive therapies [5,6]. As the benefits with transplanta-
tion are restricted, due partly to the limited availability
of organs, surgical resection remains the mainstay of
treatment [5].
Results of surgical resections show 5-year survival
rates ranging from 16% to 42% in the presence of
high tumor recurrence rates post-resection [79].
Recurrence, in particular early occurrence, is asso-
ciated with poorer long-term survival [911]. This has
urged the search for a supplementary treatment for
resection, whether neoadjuvant or adjuvant, to further
improve the survival outcome by reducing the rates of
recurrence [12]. A Hong Kong randomized con-
trolled trial using lipiodol I-131 as an adjuvant
treatment post-liver resection produced very encoura-
ging results in this regard. Lau and colleagues
reported, in their treatment group, 3-year median
overall and disease-free survival (DFS) rates of 84.8%
(p0.039) and 74.5% (p0.037), respectively [13].
The aim of this study was to determine the
effectiveness of adjuvant lipiodol I-131 on the overall
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and DFS rates following potentially curative surgery
with resection and/or ablation.
Methods
This is a retrospective review of prospectively col-
lected data. Since 1990, 329 patients with HCC have
been looked after at the St. George Hospital Liver
Unit. Of those, 97 patients have undergone curative
surgical treatment with surgical resection and/or
ablation depending on the anatomical location of the
tumors. Our selection criteria for curative treatment
included absence of extrahepatic disease and pre-
served liver function. Since macroscopically complete
extirpation of tumor would be accepted by many as
potentially curative, patients with positive margins on
histopathological assessment were included in the
study. The presence of cirrhosis, tumor thrombus,
and tumor invasion in portal and hepatic veins were
not absolute contraindications [7]. In patients with
cirrhotic livers, a supplementary indocyanine green
retention test was performed to determine the extent
of resectability. Surgical resection was performed
using the Cavitron Ultrasonic Surgical Aspirator
(CUSA), and all cryoablated tumors were assessed
by ultrasonogram to confirm complete tumor necro-
sis. Treatment was regarded as potentially curative if
the liver was macroscopically clear of all tumors post-
surgery.
All patients were offered adjuvant lipiodol I-131
after ‘‘curative’’ surgical treatment provided the dis-
ease was not present elsewhere. The lipiodol dosage
was administered based on the volume of residual
liver parenchyma post-surgery. The median treatment
interval was 1.9 months (range 1.17.9 months). The
patients were later followed up with a-Fetoprotein (a-
FP) levels, liver function test, and abdominal CT
imaging at 1 month post-discharge and at 3-monthly
intervals thereafter.
All files were reviewed by 29 September 2007. Data
was extracted for patient demographics, hepatitis
status, Child-Pugh scoring, preoperative and post-
operative a-FP levels, surgical methods, histopathol-
ogy of resected specimens, lipiodol uptake, disease
course, and survival. Overall survival and DFS were
calculated from the date of surgery and were analysed
using the Kaplan-Meier program via SPSS version
14.0 for Windows (SPSS Inc., Chicago, Ill., USA).
Results obtained were compared with those of the
original article by Lau et al. published in 1999 and
other adjuvant lipiodol I-131 studies identified.
Results
Since 1999, out of a total of 73 who were resected
and/or ablated, 33 accepted treatments with lipiodol
I-131 as postoperative adjuvant therapy. Another
patient treated with adjuvant lipiodol I-131 prior to
1999 was also included in the study. All in all, 3
patients were treated with ablation, 24 with surgical
resections, and 7 with combined ablation and resec-
tions. A total of 15 segmentectomies, 1 left lateral
resection, 3 central, 2 left, 1 extended left, 7 right, and
2 extended right hepatectomies were performed. The
dosage of lipiodol I-131 administered varied among
individual patients. The mean dosage was 1744.79
89.7 (S.E.) MBq. Median duration of interval from
surgery to lipiodol I-131 was 1.9 months (range 1.1
7.9 months).
Patient demographics and details of the disease are
briefly summarized in Table I. This study group was
made up of 24 males and 10 females aged between
25.6 and 80.7 years (median age 60.4 years). Twenty-
four cases were a result of chronic hepatitis B and C
infections, chronic alcohol consumption, and hemo-
chromatosis. However, etiologies were indeterminate
in 10 cases. Sixteen of these HCCs arose on a
background of cirrhosis.
Clinical assessments revealed 27 cases of Child-
Pugh A and 5 Child-Pugh B. Liver functions of two
other patients could not be established. Preoperative
serum a-FP concentration was obtained for all except
three patients. The median a-FP level computed was
12 ng/ml with 8 patients having levels of 400 ng/ml
and above.
Tumor characteristics were established with radi-
ological imagings and pathohistological analysis of
surgically resected specimens only. A majority of
patients (23) had solitary tumors, while 11 others
had at least 2 lesions. We recorded tumor sizes at the
maximal diameter and found that 23 patients had
lesions larger than 5.0 cm. The median tumor size
was valued at 8.0 cm (range 2.020.0 cm). Portal vein
thrombosis was evident in three patients. Microvas-
culature was involved in 13 and margins were micro-
scopically positive in 7 of the 31 resection patients.
Three fibrolamellar variants were also identified. With
respect to the degree of differentiation, 8 were well-
differentiated, 3 well to moderate, 14 moderate, and 1
was poorly differentiated. Tumor differentiation was
not reported in 2 patients.
At the time of analysis, three patients were lost to
follow-up and were excluded from both overall
survival and DFS analysis. The median duration of
follow-up was 23.3 months (range 4.994.9 months),
during which 12 patients died and tumor recurred in
22 others. The median overall survival was 40.1
months (range 5.294.9 months), while the overall
survival rates at 1, 2, 3, and 4 years were 87.1%,
71.7%, 60.7%, and 49.6%, respectively (Figure 1). As
for the resection only group, the overall survival rates
at 1, 2, 3, and 4 years were 85.7%, 67.8%, 67.8%,
and 67.8%, respectively (Figure 2). A total of two
deaths resulted from treatment-related complications.
One patient developed pneumonitis after administra-
tion of a single lipiodol I-131 dose of 1600 MBq and
died 2 months later. Another patient developed
radiation hepatitis and died of liver failure 5 months
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Table I. Summary of individual patient demographics and details.
Patient Status Age Sex R/A
Lip
I-131dose
Pre-op
AFP level
Child’s
score Cirrhosis
Tumor size
(B5 cm)
Portal Vein
Thrombus Rupture
Vascular
involvement
Margin
involvement Recurrence
AR D 74.5 M A 2000 136 B     N/A N/A 
JA D 66.3 M A 1000 3 A     N/A N/A 
OM D 69.1 M A 1600 1335 A     N/A N/A 
TA D 41.0 M R 1906 11990 B       
HN D 55.6 M R 2219 8 A       
GB D 62.8 M R 1500 8 A       
BA D 64.9 F R 1400 400 A       
ES D 61.8 M RA 1000 20 A       
FH D 73.5 M RA 2170 6 A       
LT D 61.1 F RA 800 4 B       
TDT D 55.0 F RA 2000 473 A       
KD D 80.7 M R 2000 7 A       
THA AWD 50.6 M R 2050 2785 A       
EP AWD 79.9 M R 2134 2 B       
SW AWD 25.6 M R 2000 12 A       
PSY AWD 57.0 F R 2280 73 A       
MZ AWD 57.2 F R 2053 12 A       
RR AWD 72.1 M R 1000 31 A       
CC AWD 45.3 M R 2100 195 A       
MY AWD 62.1 M R 1000 33 A       
BCD AWD 41.4 M R 469 2150 A       
JW AWD 70.5 M R 2000 4 A       
JL AWD 65.4 F R 1310         
KE AWD 59.7 F RA 1240 6 B       
VA NED 44.5 M RA 2000 168000 A       
GT NED 59.6 M RA 2200 4 A       
MDN NED 72.2 M R 2256 9 A       
XYP NED 42.8 F R 2000 205 A       
KH NED 52.7 F R 2000 35000 A       
TK NED 72.5 M R 2200  A       
GW NED 71.8 F RA 2000 B5 A       
SP NED 36.4 M R 1800 8 A       N/A
MH NED 44.9 M R 201 3 A       N/A
RD NED 45.3 M R 2000         N/A
Abbreviations: D, dead; NED, no evidence of disease; AWD, alive with disease; NA, non-applicable; M, male; F, female; A, ablation; R, resection; RA, resection and ablation.
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post-treatment with 2000 MBq of lipiodol I-131. This
patient had well-preserved liver function (Child-Pugh
A) prior to treatment albeit in the presence of
cirrhosis. We could not identify any risk factors for
radiation injury within patients.
The two treatment-related deaths were excluded
from DFS analysis. The DFS rates at 1, 2, 3, and 4
years were 61.7%, 38.7%, 16.9%, and 16.9%, re-
spectively (Figure 3 ). Median time to recurrence was
22.3 months. Within the first postoperative year,
tumor recurred in 11 patients. Three patients devel-
oped disseminated metastasis. Others with isolated
recurrences developed disease progression within the
liver (12 patients), lungs (4), bones (2), and pericar-
dial lymph nodes (1). Intrahepatic recurrences were
made up of 10 new lesions within the liver remnant
and 2 on the edge of resection. Nine of them were
further treated, with re-administration of lipiodol I-
131 in 4 patients, repeat hepatectomy in 2, RFA in 2,
and transarterial chemoembolization (TACE) in 2.
On the other hand, extrahepatic metastases were
managed with resection, radiotherapy, or systemic
chemotherapy (Table III).
Further analysis of the influence on survival by
microscopically positive margins was performed with
the log rank test. Included in the analysis were a total
of six positive cases. The overall median survival in
the positive and negative margins of resection groups
were 43.4 months and 60.7 months, respectively.
The difference between groups, however, was not
Figure 1. Overall survival of all patients receiving adjuvant lipiodol
I-131.
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Figure 2. Overall survival of patients receiving adjuvant lipiodol I-
131 post-liver resection only.
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Figure 3. Disease-free survival rate of all patients receiving adjuvant
lipiodol I-131.
Figure 4. Overall survival for resections9ablation receiving adju-
vant lipiodol I-131 according to microscopic tumor involvement of
resection margins.
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significant (p0.42). The same goes for the median
DFS (p0.90), which, for the respective positive and
negative resection margin groups, were 24.0 months
and 33.8 months.
Discussion
In a search for studies on adjuvant lipiodol I-131, four
were identified and are summarized in Table II [13
16]. Surgical resection was used in all four studies as
the curative intervention. Our series was a mix of
cryoablation and/or surgical resection. Cryoablation
has been proven relatively effective and safe, and has a
curative role [6,17,18]. Zhou et al. achieved a 3-year
survival rate of 50% in primary liver cancer (PLC)
lesions up to 5 cm in diameter, although they later
reported a lower rate of 40.3% in 78 PLCs with
cryoablation [17,18]. When used in conjunction with
liver resection for complete tumor eradication, cryoa-
blation can result in a 3-year survival rate of 52.6%
[18]. These results are similar to those of treatment
with surgical resection alone; hence, justifying our
inclusion of this locoregional therapy as a means of
curative treatment. In addition, there are established
methods of evaluating complete removal of tumors via
ablation  ultrasonography for assessments of such is
much easier with cryoablated lesions than those
radiofrequency ablated. However, the use of adjuvant
lipiodol I-131 in the post-ablative setting has not been
reported previously.
Table II. Comparison of adjuvant lipiodol I-131 studies.
Source
Lau
et al. [13]
Partensky
et al. [14]
Boucher
et al. [15]
Tabone
et al. [16]
Current
study
Study design RCT Phase II trial Case-control Case-control Retrospective study
Lipiodol I-131 dose (MBq) 1850 1110 2400 1100 1744.7989.7
Interval from surgery to lipiodol I-131 68 weeks 3 (110) months 812 weeks 3.4 (24.5 months) 1.9 (1.17.9) months
No. of patients treated 21 28 38 10 34
Males 17 24 37 10 24
Females 4 4 1  10
Age in years (median/mean) 51.0 (2371) 61.5 (3375) 6497.9 67.0 (5176) 60.4 (2581)
Tumor size (cm) [median/mean] 4.4 (1.411) 5.5 (2.529.0) 4.9790.28 5.47 (1.710) 8.0 (2.020.0)
Median AFP (ng/ml) 147 (413300) N/A N/A 33 (3.94584) 12 (2168 000)
Etiology HBV N/A N/A HCV Various
Major liver resection (%) 11 (52) 18 (64) 8 (21) 3 (30) 15 (48)
Cirrhosis N/A 7 29 10 15
Vascular invasion 1 2 14 5 16
Positive margin Nil Nil 2 Nil 7
No. of recurrences 6 12 9 6 22
No. of deaths 4 6 3 2 12
Median follow-up duration (months) 34.6 (14.169.7) 51 (593) 15 (minimum) 38 23.3 (4.994.9)
Overall survival rate (%)
1-year 90.5  94.7 100.0 87.1
2-year   83.7 80.0 71.7
3-year 84.8 86.0 68.4 80.0 60.7
4-year     49.6
5-year  65.0   
Median disease-free survival
(months)
57 28 16 25 22
Disease-free survival rate (%)
1-year 85.2  94.7 100.0 61.7
2-year   91.7 80.0 38.7
3-year 74.5  91.7 50.0 16.9
4-year     16.9
5-year  40.0   
Figure 5. Disease-free survival for resections9ablation receiving
adjuvant lipiodol I-131 according to microscopic tumor involve-
ment of resection margins.
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In the identified studies, variable single dosages of
lipiodol I-131 were standardized for all patients
irrespective of the extent of resection. While the
prudent Italian regulation on radiation exposure
allowed a dose of only 1100 MBq, the other studies
also successfully achieved tumor effect at much higher
dosages without radiation complications [1316]. In
our attempt to tally the I-131 dose with postoperative
functional remnant liver volume, two fatal complica-
tions arose in two patients with unidentified risk
factors. One was among the three who underwent
cryotherapy and one in a patient who had a major
resection (major resections accounted for 48% of all
resections). They each received 1600 and 2000 MBq
of I-131.
It is widely known that recurrences after curative
treatment of HCCs are the main cause of poor long-
term survival. This is further influenced by their time of
occurrence [10,19]. The earlier the recurrence, the less
favorable the outcome [911,19]. However, the defini-
tion of early and late is dubious, with some drawing the
line at 1 year and others at 2 years [9,10]. Multiple
studies have attempted to determine the factors pre-
dictive of the timing of recurrence and have found the
presence of microvascular and macrovascular invasion,
non-anatomical resections, serum a-FP]32 ng/ml,
tumor rupture, and cirrhosis more vulnerable to
developing recurrences early [9]. The outcome of
treatment of recurrence is variable [9,10]. Of our 22
patients with disease progression, half recurred within
the first postoperative year. Only two of them were
eligible for potentially curative treatment with resec-
tion and radiofrequency ablation (RFA).
Compared to intrahepatic recurrences, the preva-
lence of extrahepatic metastases in general, is lower;
the lungs being the most common site [20]. Amid the
unavailability of effective systemic treatment for this
pattern of recurrence, we observed one patient treated
with chemotherapy for lung disease at month 7 post-
resection living for another 41.4 months thereafter. A
similar scenario was observed in another patient who
survived another 25 months after treatment of recur-
rence. New agents may also improve results. A recent
randomized trial with sorafenib used to treat advanced
HCCs had shown promising results [21].
Tumor size is another well-established adverse
prognostic factor for recurrence and patient survival
[22]. Historically, large tumors were not surgically
managed due to the associated high postoperative
morbidity and mortality rates, as major hepatectomies
are usually required and their prognosis is usually
further worsened in the presence of cirrhosis [12].
However, more recent studies show improved long-
term survival rates ranging from 16% to 28% when
managed aggressively [8,12]. Also, their postoperative
mortality rate is now comparable to that of lesions
smaller than 5 cm [8]. From our data, 6 of the 16
patients with lesions exceeding 8 cm were associated
with cirrhosis. The actual median survival for patients
with large tumors, defined as any lesions more than
8 cm in maximal diameter, was 45.9 months. One
patient with a 13.0 cm lesion remained disease-free
after 7.5 years post-right hepatectomy with a positive
margin.
Large tumor size is also commonly accompanied by
markedly elevated serum a-FP concentration [23,24].
In fact, our data were contrary to this finding. Eight
patients with lesions over 8 cm in size had a-FP levels
below 400 ng/ml.
The effect of resection margin size in this cohort
is negligible. A study from Germany showed that
positive margins with CUSA resection had no influ-
ence on local recurrence, although it should be noted
that this study looked at liver metastasis from color-
ectal carcinoma [25]. The involvement of margin in a
CUSA resection may still mean that there is a 1 cm or
so real margin.
Compared with the other adjuvant lipiodol I-131
studies, several of our parameters had been identified
to be within their range. These include the lipiodol
dosage, interval from time of surgery to lipiodol I-131,
age, proportion of major resection, and number of
vascular invasions and cirrhosis (Table II). None-
theless, we have a notable proportion of larger
tumors, which may have played a significant role in
the higher tumor recurrence rate and much poorer
DFS rates of this study. The early recurrences may
also have otherwise been attributed to HBV infec-
tions. Eleven of the HCCs diagnosed were HBV-
related. This number could be higher, because
etiology was indeterminate in 10 cases. However,
our long-term survival rates were comparable in spite
of 45% extrahepatic recurrence. Plus, analysis of the
resection-only group showed a 4-year survival rate of
67.8%. It may be argued that treatment of recurrences
might have contributed to the resulting good overall
survival. However, there is evidence that such treat-
ments have no impact at all [10]. Moreover, only
5 patients (22.7%) within this study were eligible for
potentially curative treatments (Table III).
Previous attempts at adjuvant therapy have included
negative studies with oral carmofur (1-hexylcarba-
moyl-5-fluorouracil (HCFU)) and a combination of
uracil and tegafur [26,27]. Postoperative TACE
showed no benefits either [2628]. In addition, a study
on preoperative TACE reduced the long-term survival
[29]. On the other hand, Muto et al. [30] reported
reduction of multicentric recurrences with polyprenoic
acid (retinoid) after surgical resection or percutaneous
ethanol injection (PEI), but the effect on DFS was not
significant. Later, an RCT using adoptive immu-
notherapy adjuvantly resulted in prolonged time to
development of recurrence and improved DFS rates
but not long-term survival [31]. A more recent trial
with adjuvant PI-88, a heparanase and VEGF activity
inhibitor, also suggested similar benefits on disease
progression [32]. Suppression of viral replication with
postoperative treatments using interferon a and b had
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successfully reduced the rate of recurrences in HBV
and HCV-related HCCs, respectively [3335].
Although the use of adjuvant lipiodol I-131 post-
surgical treatments may not have prevented recur-
rences or prolonged the DFS, it has significantly
improved the rates of intrahepatic recurrence. Com-
pared to a study previously reporting an intrahepatic
recurrence rate of 88% [22], our rates were much
lower (Table III). In conclusion, our trial with
adjuvant lipiodol I-131 has proven beneficial on
overall survival in the short term.
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